Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Repetitive Transcranial Magnetic Stimulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TMS | ACTIVE_COMPARATOR | Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 6 weeks |
| Placebo | PLACEBO_COMPARATOR | Treatment 5 days/week for up to 6 weeks |
| Name | Type | Description |
|---|---|---|
| Repetitive Transcranial Magnetic Stimulation | DEVICE | - |
Inclusion Criteria: * Primary diagnosis by DSM-IV criteria for Major Depressive Episode, single or recurrent episode as confirmed by the Structured Clinical Interview for the DSM-IV (SCID-IV), with the additional stipulation of a duration for this episode of greater than or equal to 4 weeks and CGI...
Top 20 of 29 competitors
Repetitive Transcranial Magnetic Stimulation (rTMS) is used for the treatment of Major Depressive Disorder. It is an investigational therapy being studied in a Phase 3 clinical trial. The treatment is delivered using a device developed by Neuronetics, Inc. for patients with this psychiatric condition.
Repetitive Transcranial Magnetic Stimulation is developed by Neuronetics, Inc., a company traded on the stock exchange under the ticker symbol STIM. The company is conducting clinical research to evaluate this treatment for Major Depressive Disorder.
Repetitive Transcranial Magnetic Stimulation is in Phase 3 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the treatment is being studied for Major Depressive Disorder.
Repetitive Transcranial Magnetic Stimulation has one completed Phase 3 clinical trial registered under NCT00104611. This study, titled 'Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder,' enrolled 286 participants in the United States. The trial was randomized, double-blind, and placebo-controlled.
Repetitive Transcranial Magnetic Stimulation is not FDA approved. It is an investigational therapy currently in Phase 3 clinical development for Major Depressive Disorder. The Phase 3 trial has been completed, but approval status has not been established.